These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 23611368)

  • 1. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
    Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
    Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
    Gremmel T; Xhelili E; Steiner S; Koppensteiner R; Kopp CW; Panzer S
    Atherosclerosis; 2014 Jan; 232(1):119-24. PubMed ID: 24401225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Transl Res; 2013 May; 161(5):421-9. PubMed ID: 23340049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
    Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S
    Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2014 Mar; 111(3):474-82. PubMed ID: 24196591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
    Badr Eslam R; Lang IM; Kaider A; Panzer S
    Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity.
    Gremmel T; Kopp CW; Seidinger D; Giurgea GA; Koppensteiner R; Steiner S; Panzer S
    Atherosclerosis; 2009 Dec; 207(2):608-13. PubMed ID: 19616779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.
    Gremmel T; Durstberger M; Eichelberger B; Koppensteiner R; Panzer S
    Cardiovasc Ther; 2015 Oct; 33(5):264-9. PubMed ID: 26014752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
    Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
    Postgrad Med J; 2006 Jun; 82(968):404-10. PubMed ID: 16754711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?
    Gremmel T; Calatzis A; Steiner S; Kaider A; Seidinger D; Koppensteiner R; Kopp CW; Panzer S
    Platelets; 2010; 21(7):515-21. PubMed ID: 20624009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
    Xiao Z; Théroux P
    J Am Coll Cardiol; 2004 Jun; 43(11):1982-8. PubMed ID: 15172401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Antiplatelet Effect of Clopidogrel Decreases With Patient Age.
    Xhelili E; Eichelberger B; Kopp CW; Koppensteiner R; Panzer S; Gremmel T
    Angiology; 2016 Nov; 67(10):902-908. PubMed ID: 26861857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
    Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
    Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
    Gremmel T; Koppensteiner R; Panzer S
    PLoS One; 2015; 10(6):e0129666. PubMed ID: 26058047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
    Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
    Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.